GTAM
LCTX icon

Global Trust Asset Management’s Lineage Cell Therapeutics LCTX Stock Holding History

Global Trust Asset Management’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-200
Closed – – 423
2019
Q1 		$0 Hold
200
– – ﹤0.01% 417
2018
Q4 		$0 Buy
+200
New +$306 ﹤0.01% 430

Other funds holding LCTX

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
PGP
Prescott General Partners Boca Raton, Florida $1.37B AUM 23.81% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Global Trust Asset Management's LCTX Position: Q2 2019 in Review

Global Trust Asset Management sold out of Lineage Cell Therapeutics (LCTX) in Q2 2019, closing a stake of 200 shares.

Global Trust Asset Management first reported a position in LCTX in Q4 2018 and held it in 2 quarters. The position peaked at $0 in Q1 2019. 107 funds tracked by Wall St. Rank hold LCTX as of Q2 2019.

  • Global Trust Asset Management reported no remaining Lineage Cell Therapeutics position as of Q2 2019 after selling out during the quarter.
  • Global Trust Asset Management sold 200 Lineage Cell Therapeutics shares in Q2 2019.
  • Global Trust Asset Management first reported a position in Lineage Cell Therapeutics in Q4 2018 and held it in 2 quarters.
  • Global Trust Asset Management's Lineage Cell Therapeutics position peaked at $0 in Q1 2019.
  • 107 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q2 2019.

Based on Global Trust Asset Management's 13F filing for Q2 2019, filed 23 Jul 2019.